BNT-321 is under clinical development by BioNTech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BNT-321’s likelihood of approval (LoA) and phase transition for Metastatic Adenocarcinoma of The Pancreas took place on 04 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BNT-321 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BNT-321 overview

MVT-5873 is under development for the treatment of metastatic adenocarcinoma of the pancreas, cholangiocarcinoma, pancreatic ductal adenocarcinoma and metastatic colorectal cancer.. It is administered intravenously. It is a recombinant human IgG antibody that acts by targeting carbohydrate antigen sialyl-Lewis(a), also known as CA19.9. The drug candidate is developed based on human antibody discovery platform.

It was also under development for the treatment of CA19-9 positive malignancies including gastrointestinal cancer (colon cancer), non-small cell lung cancers, small cell lung cancers.

BioNTech overview

BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

Quick View BNT-321 LOA Data

Report Segments
  • Innovator
Drug Name
  • BNT-321
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: BioNTech
  • Originator: MabVax Therapeutics Holdings
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.